Hepatocellular Carcinoma: Immune Checkpoint Inhibitors, Multi-Targeted Tyrosine Kinase Inhibitors and the Combination Thereof – Enduring Webcast

Description

Program Description

---

Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide and represents a major global healthcare challenge. Although viral hepatitis and alcohol remain essential risk factors, non-alcoholic fatty liver disease is rapidly becoming a dominant cause of HCC. A broad range of treatment options is available for patients with HCC, including liver transplantation, surgical resection, percutaneous ablation, radiation, and transarterial and systemic therapies. Clinical decision-making requires a multidisciplinary approach that longitudinally adapts the individual treatment strategy according to the patient’s tumor stage, liver function, and performance status. With the approval of new first-line and second-line agents and the establishment of immune checkpoint inhibitor-based therapies as the standard of care, the treatment landscape of advanced HCC is more diversified than ever.

Consequently, the outlook for patients with HCC has improved. However, the optimal sequencing of drugs remains to be defined, and predictive biomarkers are urgently needed to inform treatment selection. Update on the causes, diagnosis, molecular classification, and treatment of HCC is the focus of this activity.

Intended Audience

---

Oncologists, hepatologists, physician assistants, nurse practitioners, registered nurses, and other investigators on the latest advances in the treatment of HCC.

Commercial Supporter

---

This activity is supported by an educational grant from Exelixis.